Meningococcal disease: PGD template for supply of ciprofloxacin
- Public Health England
- Part of:
- Meningococcal disease: guidance, data and analysis
- First published:
- 17 February 2017
Patient group direction (PGD) template to supply ciprofloxacin for meningococcal disease clusters of 2 or more cases in a congregate setting.
Ref: PHE publications gateway number: 2016635 MS Word Document, 253KB
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
This PGD template is to support the supply of ciprofloxacin to adults and children for the management of clusters of meningococcal disease, when 2 or more cases are reported in a congregate setting. It is valid from 10 February 2017 until 10 February 2020.
It can be used when a decision has been made by a consultant in health protection or a consultant in public health medicine to offer chemoprophylaxis to:
- children and staff of the same preschool group
- children of the same school year
- children or students who share a common social activity or a group of friends
The PGD template requires further authorisation, by a clinical governance or patient safety lead who has designated responsibility for signing PGDs, so it meets legal requirements for a PGD. The PGD is not legal or valid without this local, formal authorisation.
Adoption and governance of the use of this PGD is the responsibility of the authorising commissioning body and providers.
Provider organisations and health professionals should check they are working to the current PGD versions and only work to a legally authorised PGD from their commissioning body.
Published: 17 February 2017